A detailed history of Global Retirement Partners, LLC transactions in Intra Cellular Therapies, Inc. stock. As of the latest transaction made, Global Retirement Partners, LLC holds 241 shares of ITCI stock, worth $18,101. This represents 0.0% of its overall portfolio holdings.

Number of Shares
241
Previous 765 68.5%
Holding current value
$18,101
Previous $52,000 69.23%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 23, 2024

SELL
$64.76 - $79.84 $33,934 - $41,836
-524 Reduced 68.5%
241 $16,000
Q1 2024

Apr 23, 2024

SELL
$64.37 - $75.65 $31,927 - $37,522
-496 Reduced 39.33%
765 $52,000
Q4 2023

Jan 18, 2024

SELL
$46.37 - $73.65 $22,814 - $36,235
-492 Reduced 28.07%
1,261 $90,000
Q3 2023

Oct 13, 2023

BUY
$52.09 - $64.1 $11,095 - $13,653
213 Added 13.83%
1,753 $91,000
Q1 2023

May 05, 2023

BUY
$43.8 - $56.99 $65,700 - $85,485
1,500 Added 3750.0%
1,540 $83,000
Q1 2022

Jul 14, 2022

BUY
$38.74 - $62.09 $1,549 - $2,483
40 New
40 $2,000
Q4 2021

Jan 21, 2022

SELL
$35.2 - $53.42 $30,377 - $46,101
-863 Closed
0 $0
Q2 2021

Jul 15, 2021

SELL
$29.3 - $44.5 $1,201 - $1,824
-41 Reduced 4.54%
863 $35,000
Q1 2021

Apr 14, 2021

BUY
$30.8 - $39.51 $369 - $474
12 Added 1.35%
904 $31,000
Q4 2020

Jan 13, 2021

BUY
$23.34 - $32.22 $863 - $1,192
37 Added 4.33%
892 $28,000
Q3 2020

Oct 09, 2020

BUY
$17.61 - $31.86 $1,989 - $3,600
113 Added 15.23%
855 $22,000
Q2 2020

Jul 13, 2020

BUY
$14.35 - $26.64 $4,061 - $7,539
283 Added 61.66%
742 $19,000
Q1 2020

Apr 28, 2020

SELL
$12.31 - $33.12 $603 - $1,622
-49 Reduced 9.65%
459 $7,000
Q4 2019

Jan 23, 2020

SELL
$7.26 - $38.49 $3,100 - $16,435
-427 Reduced 45.67%
508 $17,000
Q3 2019

Nov 19, 2019

BUY
$7.47 - $14.03 $6,984 - $13,118
935 New
935 $7,000

Others Institutions Holding ITCI

About Intra-Cellular Therapies, Inc.


  • Ticker ITCI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 94,401,696
  • Market Cap $7.09B
  • Description
  • Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...
More about ITCI
Track This Portfolio

Track Global Retirement Partners, LLC Portfolio

Follow Global Retirement Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Global Retirement Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Global Retirement Partners, LLC with notifications on news.